Cooper Companies Inc (NYSE:COO) – Analysts at Northcoast Research decreased their Q3 2019 earnings per share estimates for Cooper Companies in a research report issued on Friday, May 31st. Northcoast Research analyst D. Keiser now expects that the medical device company will earn $3.18 per share for the quarter, down from their prior forecast of $3.20. Northcoast Research has a “Buy” rating and a $340.00 price objective on the stock. Northcoast Research also issued estimates for Cooper Companies’ Q4 2019 earnings at $3.31 EPS, FY2019 earnings at $12.30 EPS, Q2 2020 earnings at $3.25 EPS and Q4 2020 earnings at $3.66 EPS.

Cooper Companies (NYSE:COO) last released its quarterly earnings data on Thursday, May 30th. The medical device company reported $2.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.76 by $0.18. Cooper Companies had a return on equity of 17.25% and a net margin of 16.46%. The company had revenue of $654.30 million during the quarter, compared to the consensus estimate of $655.00 million. During the same quarter in the prior year, the firm posted $2.86 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year.

COO has been the subject of several other research reports. Zacks Investment Research downgraded Cooper Companies from a “hold” rating to a “sell” rating in a research note on Tuesday, February 5th. Wells Fargo & Co upped their price objective on Cooper Companies from $305.00 to $325.00 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Stephens upped their price objective on Cooper Companies from $305.00 to $320.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. KeyCorp upped their price objective on Cooper Companies from $296.00 to $314.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $325.00 price objective on shares of Cooper Companies in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Cooper Companies currently has an average rating of “Buy” and a consensus target price of $309.36.

Cooper Companies stock opened at $310.61 on Monday. Cooper Companies has a 1 year low of $221.50 and a 1 year high of $311.18. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.21 and a quick ratio of 0.68. The company has a market capitalization of $14.90 billion, a PE ratio of 27.01, a PEG ratio of 2.26 and a beta of 0.78.

A number of large investors have recently added to or reduced their stakes in COO. Essex Savings Bank acquired a new stake in Cooper Companies during the 4th quarter valued at approximately $25,000. Certified Advisory Corp bought a new position in shares of Cooper Companies during the 4th quarter worth approximately $25,000. Executive Wealth Management LLC bought a new position in shares of Cooper Companies during the 4th quarter worth approximately $34,000. Financial Gravity Companies Inc. bought a new position in shares of Cooper Companies during the 4th quarter worth approximately $46,000. Finally, Quadrant Capital Group LLC boosted its holdings in shares of Cooper Companies by 827.8% during the 1st quarter. Quadrant Capital Group LLC now owns 167 shares of the medical device company’s stock worth $47,000 after buying an additional 149 shares in the last quarter. 96.18% of the stock is owned by institutional investors and hedge funds.

In other Cooper Companies news, SVP Agostino Ricupati sold 2,400 shares of the stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $296.13, for a total transaction of $710,712.00. Following the completion of the sale, the senior vice president now owns 400 shares of the company’s stock, valued at approximately $118,452. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert D. Auerbach sold 2,272 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $292.22, for a total transaction of $663,923.84. Following the sale, the insider now directly owns 2,538 shares of the company’s stock, valued at approximately $741,654.36. The disclosure for this sale can be found here. Insiders have sold a total of 87,030 shares of company stock valued at $25,461,465 in the last three months. Insiders own 1.70% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Further Reading: What does a bar chart display?

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.